Tropisetron
Navoban
Tropisetron (Navoban) is a healing & recovery research compound. 5-HT3 antagonist and alpha-7 nicotinic receptor partial agonist. That second action is the interesting one — alpha-7 activation on immune cells is the cholinergic anti-inflammatory pathway.
Tropisetron quick facts
| Reported research dose | 5mg daily (approved antiemetic dose) |
| Route | Oral |
| Frequency | 1x |
| Half-life | ~6 hours (longer in poor CYP2D6 metabolizers) |
| Forms | Oral |
| Evidence level | Approved as an antiemetic; the anti-inflammatory and fibromyalgia use rests on weaker data |
The alpha-7 mechanism is why it appears in nootropic and anti-inflammatory discussions rather than just antiemetic ones. Small trials in fibromyalgia showed benefit. ⚠️ QT prolongation — the intravenous form was restricted in some markets for that reason.
How Tropisetron works
5-HT3 antagonist and alpha-7 nicotinic receptor partial agonist. That second action is the interesting one — alpha-7 activation on immune cells is the cholinergic anti-inflammatory pathway.
Proposed benefits
Researched for soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
Where to get Tropisetron
Buy Tropisetron at Disguised Alpha →The evidence for Tropisetron
Graded by what exists behind each claim.
✅ Clinically validated
- Approved in Europe and elsewhere as an antiemetic with solid trial data. Separately, small randomized trials in fibromyalgia reported pain reduction — an unexpected finding that generated the off-label interest.
📊 Correlative data
- Limited community use, mostly for fibromyalgia and inflammatory pain on the strength of those small trials. Long antiemetic use in oncology gives a well-characterized tolerability profile — headache and constipation are the common complaints — but that record says nothing about the analgesic claim, which rests entirely on the small trials above.
🧪 Theoretical / extrapolated
- A 5-HT3 receptor antagonist. The antiemetic action is straightforward; the analgesic claim rests on 5-HT3 receptors on peripheral nociceptors and spinal interneurons, plus α7 nicotinic receptor activity with anti-inflammatory effects.
- The α7 pathway is the more interesting mechanism and the less established one — it is the same cholinergic anti-inflammatory reflex that vagal stimulation targets.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Tropisetron actually does
Tropisetron does two opposite things to two ion channels, and the reason one molecule can is that the two channels are relatives. It is a 5-HT3 receptor antagonist and, at the same time, a potent α7 nicotinic acetylcholine receptor agonist Hashimoto 2015. Block one, activate the other. That looks like a coincidence until you notice that 5-HT3 and α7 nAChR are both Cys-loop pentameric ligand-gated ion channels — the same structural superfamily, five subunits around a central pore, an extracellular binding pocket at the subunit interface. A small molecule shaped to fit one pocket has a real chance of fitting the other. The dual pharmacology is family resemblance.
The antiemetic half, which is the approved half. 5-HT3 is the only ionotropic serotonin receptor — every other 5-HT receptor is a G-protein-coupled receptor. It sits on vagal afferent terminals in the gut, and chemotherapy-damaged enterochromaffin cells dump serotonin onto it, depolarizing the nerve and starting the emetic reflex. Kutz 1993 describes the drug as a highly selective 5-HT3 receptor antagonist that selectively blocks the excitation of the presynaptic 5-HT receptors of the peripheral neurones involved in the emetic reflex, and that is what it was licensed for: nausea and vomiting from highly emetogenic chemotherapy such as cisplatin.
The half that puts it on a research site is the α7. The α7 nicotinic receptor is unusually calcium-permeable for a nicotinic channel, and it is expressed on macrophages and other immune cells as well as on neurons. That is the efferent limb of the cholinergic anti-inflammatory pathway: vagal acetylcholine acting on macrophage α7 suppresses cytokine release. So the anti-inflammatory claim made for this drug is not a hand-wave — it has a named receptor, a named cell type and a named pathway. What it does not yet have, anywhere in the human literature, is a measured cytokine.
And there is a third target that almost nobody mentions. Hashimoto 2015 reports that tropisetron also binds the ectodomain of amyloid precursor protein, and that in the models reviewed it promoted greater improvements in memory than current Alzheimer’s therapeutics such as memantine and donepezil. Three targets, three chemistries, one 1980s antiemetic. The honest statement is that the receptor pharmacology here is unusually rich and the human evidence for anything beyond vomiting is unusually thin.
Cell, rodent, human — and where it stops
Step one, receptor pharmacology. Antagonist at 5-HT3, agonist at α7 nAChR, binder of the APP ectodomain Hashimoto 2015; a highly selective 5-HT3 antagonist by the developer’s own characterization Kutz 1993.
Step two, humans, the approved indication. Active against nausea and vomiting induced by highly emetogenic chemotherapy, at 5 mg daily Kutz 1993. This is the one use with a regulatory dossier behind it.
Step three, humans, fibromyalgia — and this is the single most useful published sentence about the drug. Spath 2004 reviewed the dose-finding work, in which tropisetron was given intravenously or orally at dose levels ranging from 2 mg to 15 mg daily. A significant reduction in pain intensity was achieved at 5 mg per day. And then: in the 15 mg group the decrease in pain was less than in the placebo group, while constipation and other gastrointestinal symptoms became more frequent. That is an inverted, bell-shaped dose-response — three times the dose was worse than no drug at all — and it is the opposite of how almost everybody reasons about dosing a compound they think is working.
Step four, humans, the cognitive and sensory work. Tsitsipa 2022 systematically reviewed eleven eligible studies of selective 5-HT3 antagonists and sensory processing. The consistent, robust result across five studies was that ondansetron and tropisetron improved sensory gating in patients with schizophrenia; tropisetron additionally improved sustained visual attention in non-smoking patients. Hold onto that qualifier — non-smoking — because nicotine is itself an α7 agonist, and a subgroup effect that appears only in people whose α7 receptors are not already being driven is exactly what the mechanism predicts.
The obstacle, stated exactly. Nothing here failed to cross from animal to human — every step above is human. What is missing is the link between the two receptors and the two outcomes. Not one trial has measured an α7-dependent read-out — a cytokine, a stimulated-whole-blood TNF — alongside the pain or cognition endpoint, so the α7 explanation for a clinical effect is inference from receptor pharmacology and nothing more. And the fibromyalgia dose-response is inverted, which means the useful dose window is narrow and has an upper edge nobody has mapped Spath 2004. A drug with a bell-shaped curve and no biomarker is one somebody will overshoot.
Tropisetron pharmacokinetics — how much of it actually gets in
Route: oral or intravenous, both used in the human work Spath 2004, at an approved antiemetic dose of 5 mg daily Kutz 1993. It is orally active, which is why it turns up outside a hospital at all.
What degrades it, and this is the whole pharmacokinetic story: one polymorphic cytochrome. Kutz 1993 states that tropisetron metabolism is linked to the cytochrome P450 2D6 isoenzyme system, which determines the polymorphism of debrisoquine/sparteine metabolism, and that there are phenotypic populations of extensive and poor metabolizers. The observable consequence in the tolerability studies was that adverse events were slightly more intense and lasted longer in poor metabolizers. Pharmacokinetics were similar in elderly patients and in renal patients compared with healthy subjects — which is the clean statement that the liver, not the kidney, sets exposure.
The oral barrier is CYP2D6 first-pass, and that makes the interaction list unusual. A strong CYP2D6 inhibitor — paroxetine, fluoxetine, bupropion, quinidine — converts a genetically extensive metabolizer into a functional poor one. That is phenoconversion, and on this drug it is invisible: there is no assay, no therapeutic range and no routine genotyping, so somebody on a common antidepressant is taking a different exposure from the same tablet with nothing to tell them.
The arithmetic that nobody has done, and it is the most useful thing on this page. Two published facts have never been put in the same room. Fact one: the effect is bell-shaped — 5 mg helped, 15 mg was worse than placebo Spath 2004. Fact two: clearance runs through a polymorphic enzyme with distinct poor-metabolizer and extensive-metabolizer populations Kutz 1993. Put them together and the prediction writes itself: a poor metabolizer taking 5 mg may be sitting where an extensive metabolizer sits at 10 or 15 mg — that is, past the top of the curve and on the far side where the published pain response was worse than placebo. The developer’s own conclusion was that 5 mg can be given to both poor and extensive metabolizers without particular precautions Kutz 1993, and that conclusion was reached for an antiemetic endpoint, where more blockade is simply more antiemesis. It does not transfer to a bell-shaped endpoint, and nobody has re-examined it for one.
What would have to be true, and how you would know it was not
Four predictions. Two are biomarkers, one is a dose experiment that runs backwards from intuition, and the fourth cuts against the compound in a specific population.
1. If the α7 cholinergic anti-inflammatory pathway is actually engaged, inflammation markers should fall. Draw hs-CRP and TNF-alpha at baseline and at 8 weeks on a stable dose. The mechanism is specific: α7 agonism on macrophages suppresses cytokine release, and tropisetron is described as a potent α7 agonist Hashimoto 2015. This has never been measured in a tropisetron trial, so it is a genuinely new number rather than a confirmation. If both markers are flat while constipation says the drug is clearly present, the α7 explanation for any felt benefit is wrong and something else is operating.
2. The dose prediction that runs backwards, and it is the sharpest falsification on the page. Spath 2004 found 15 mg produced less pain reduction than placebo while 5 mg produced a significant one. So the prediction is that increasing the dose should make the outcome worse, not better. Anybody who escalates because 5 mg “is not enough” is running the published experiment in the direction it already failed.
3. Constipation is the cheapest exposure marker anyone has. 5-HT3 blockade slows colonic transit, and constipation was one of the two main adverse events in the tolerability studies Kutz 1993 and rose with dose in the fibromyalgia work Spath 2004. Keep a bowel diary for 14 days before and 14 days after starting. Constipation appearing means the drug is present at a pharmacologically real concentration; no constipation and no effect is the signature of low exposure — which on this molecule points at CYP2D6 rather than at the tablet.
4. The prediction that cuts against it: a nicotine user should get nothing cognitive. Tsitsipa 2022 found the sustained visual attention benefit in non-smoking patients. Nicotine is an α7 agonist, so a smoker, vaper or pouch user is already driving the receptor this drug is supposed to drive. Test it with a Trail Making Test at the same hour, baseline and 8 weeks. A heavy nicotine user reporting a large cognitive effect is reporting something the α7 mechanism does not predict, and the honest reading of that is expectation rather than pharmacology.
What nobody has tested yet
Nobody has genotyped CYP2D6 against the bell-shaped dose-response. The two facts sit in separate papers Kutz 1993 Spath 2004 and have never been combined. The experiment is small and completely defined: genotype CYP2D6, give 5 mg, measure a plasma concentration and a pain score, and ask whether the optimal concentration is the same across phenotypes while the optimal milligram dose is not. If it is, then the whole class of “it stopped working so I took more” reports has a pharmacogenetic explanation.
Nobody has measured a cytokine on this drug in a person. The α7 anti-inflammatory pathway is the entire rationale for using tropisetron outside oncology Hashimoto 2015, and stimulated-whole-blood TNF is a routine assay. Not one of the eleven studies reviewed by Tsitsipa 2022, and none of the fibromyalgia work Spath 2004, reported one. This is the largest, cheapest hole in the literature for this compound.
Nobody has tested the nicotine interaction prospectively. The non-smoker finding is an observation drawn across studies Tsitsipa 2022, not a designed comparison. Randomizing smokers and non-smokers, or running a within-subject comparison across a nicotine abstinence period, would settle whether α7 occupancy explains the cognitive effect — and would be the first direct human test of the α7 hypothesis for this molecule.
And nobody has taken the amyloid precursor protein finding anywhere. Binding to the APP ectodomain Hashimoto 2015 is a completely different mechanism from either ion channel, it was reported over a decade ago, and there is no human study of it. It is either a lead nobody funded or an artefact nobody chased, and the literature does not currently let you tell which.
Tropisetron — its own safety story, not its class's
The most important safety fact about tropisetron on this site is a combination, and it is written on another drug’s label. Apomorphine is contraindicated with 5-HT3 antagonists — the APOKYN label names ondansetron, granisetron, dolasetron, palonosetron and alosetron — because of reports of profound hypotension and loss of consciousness when apomorphine was given with ondansetron U.S. Food and Drug Administration 2025. Every drug on that list is a 5-HT3 antagonist marketed in the United States; tropisetron is not marketed there and so does not appear on it, but it is the same pharmacological class acting at the same receptor. Anybody holding both compounds in the same cupboard should read that accordingly.
Its own routine adverse events, as the developer reported them. Headache and constipation were the two main adverse events in human volunteer tolerability studies, and both were slightly more intense and longer-lasting in poor CYP2D6 metabolizers Kutz 1993. In the fibromyalgia dose-finding work, constipation and other gastrointestinal symptoms increased at 15 mg Spath 2004. The constipation is not incidental — it is the same 5-HT3 blockade that produces the antiemetic effect, acting on colonic transit, which is why it tracks dose so reliably.
The dose-response itself is a safety finding, not just an efficacy one. A compound whose published pain response at 15 mg was worse than placebo Spath 2004 has a ceiling that punishes escalation. That is unusual and it inverts the normal self-experiment heuristic. The preclinical toxicology, for what it is worth, was unremarkable: generally well tolerated by all animal species investigated, with no specific organ toxicity other than slight loss of body weight development Kutz 1993 — so the risk here is not organ damage, it is being on the wrong side of the curve.
And the regulatory fact that changes what you are actually holding. Unlike doxepin or losartan, tropisetron has no FDA approval and no United States prescribing information. There is no US label to check a dose against, no US pharmacopoeial monograph, and material obtained outside a pharmacy carries no identity or purity guarantee for a drug whose useful window sits between 2 and 5 mg Spath 2004. On a molecule where 15 mg was worse than nothing, an unverified milligram figure on a label is not a small problem.
Sources read for this page
- Kutz K. Pharmacology, toxicology and human pharmacokinetics of tropisetron.. Ann Oncol 1993 · PMID 8363993
- Spath M. Treatment of fibromyalgia with tropisetron--dose and efficacy correlations.. Scand J Rheumatol Suppl 2004 · PMID 15515418
- Hashimoto K. Tropisetron and its targets in Alzheimer's disease.. Expert Opin Ther Targets 2015 · PMID 25399811
- Tsitsipa E. Selective 5HT3 antagonists and sensory processing: a systematic review.. Neuropsychopharmacology 2022 · PMID 35017671
- U.S. Food and Drug Administration. APOKYN (apomorphine hydrochloride injection), for subcutaneous use - full prescribing information (NDA 021264).. FDA approved labeling, revision 2025
Tropisetron — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Tropisetron — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Tropisetron moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Tropisetron in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Tropisetron
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Tropisetron — frequently asked questions
What is Tropisetron?
Tropisetron (Navoban) is a healing & recovery research compound. 5-HT3 antagonist and alpha-7 nicotinic receptor partial agonist. That second action is the interesting one — alpha-7 activation on immune cells is the cholinergic anti-inflammatory pathway.
Is the full Tropisetron protocol on this page?
The reported research dose is on this page, along with how Tropisetron works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Tropisetron?
Tropisetron has an approximate half-life of ~6 hours (longer in poor CYP2D6 metabolizers), which is part of what determines how often it's dosed.
What's the evidence behind Tropisetron?
Current evidence level: Approved as an antiemetic; the anti-inflammatory and fibromyalgia use rests on weaker data. Tropisetron is offered for research purposes only and is not an approved medicine.
What Tropisetron is used for
Tropisetron appears under 2 goals in the goal router.
Related Healing & Recovery compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.